Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 17.02.2026 FTEI.LN IE000TIZ5AP4 50,002.00 EUR 1,034,539.66 20.690  ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical sends cease-and-desist letters to protect SAINT, an FDA-cleared breakthrough in accelerated, personalized depression treatment....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Nuclear Power UCITS ETF 17.02.2026 RCTR.LN IE000J5PESP7 50,002.00 USD 1,001,039.24 20.020  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 17.02.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,374,217.59 27.483  ...

WARSAW, Poland--(BUSINESS WIRE)--Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw...

DENVER, Colorado--(BUSINESS WIRE)--Liberty Global Ltd. announces its Q4 2025 financial results. CEO Mike Fries stated, “In the fourth quarter, we continued to execute our plans to both drive commercial momentum in our telecom operations and unlock value for shareholders. Liberty Telecom: We delivered all full-year guidance metrics at VMO2, VodafoneZiggo and Telenet, reflecting growing commercial progress despite challenging competitive environments. VMO2 delivered a sequential improvement in br...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into...

DALLAS--(BUSINESS WIRE)--Palogic Value Fund, LP and Palogic Value Management, LP (collectively, “Palogic,” “we” or “our”) issued the following letter on February 17, 2026, to the Board of Trustees (the “Board”) of Pebblebrook Hotel Trust (“Pebblebrook,” or the “Company”) (NYSE: PEB). February 17, 2026 Pebblebrook Hotel Trust c/o Corporate Secretary 4747 Bethesda Avenue, Suite 1100 Bethesda, Maryland 20814 Dear Members of the Board: Palogic is highly encouraged by the steps Pebblebrook has recen...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Fraser Yachts (“Fraser”), a leading global superyacht brokerage and services company and a wholly owned subsidiary of MarineMax, Inc. (NYSE: HZO) (“MarineMax”), today announced a strong start to 2026, completing 12 superyacht sales in just 12 days during January. The transactions included a balanced mix of brokerage and new‑build activity involving some of the industry’s most established shipyards, including Lürssen, Feadship, Abeking & Rasmussen, and...

MIAMI--(BUSINESS WIRE)--As travelers increasingly seek out experiences that go beyond crowded ports and one-size-fits-all cruising, Windstar Cruises is leaning into what it does best: offering intimate small-ship journeys with uncommon access and deeper cultural discovery. That approach comes into full focus with the opening of bookings for Windstar’s Winter 2027-2028 season, which features a global lineup of more than 230 sailing dates, 21 new itineraries, and six luxury yachts sailing between...